Highlights include a real-world comparison of Wegovy 2.4 mg against resmetirom in MASH and ESSENCE data in people with a BMI under 27, presented Nov. 5 to 9 in Denver.
Recap by typeshit. Full story at Yahoo Finance.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Novo presented the post hoc look at its phase 3 trial at The Menopause Society Annual Meeting, focusing on results for women taking the combination shot.
Hair loss linked to GLP-1 receptor agonists appears at comparable rates by race, Medscape reports, adding detail on a side effect many users ask about.
Loading…